Biomea Fusion, Inc. (BMEA)
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.
Address
900 MIDDLEFIELD ROAD
REDWOOD CITY, CA 94063
Founded
2017
Number of Employees
103
Website
http://biomeafusion.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)